Evaluation of medical devices via clinical trial is often a necessary step in the process of bringing a new product to market. In recent years, device manufacturers are increasingly using stochastic engineering models during the product development process. These models have the capability to simulate virtual patient outcomes. This article presents a novel method based on the power prior for augmenting a clinical trial using virtual patient data. To properly inform clinical evaluation, the virtual patient model must simulate the clinical outcome of interest, incorporating patient variability, as well as the uncertainty in the engineering model and in its input parameters. The number of virtual patients is controlled by a discount function which uses the similarity between modeled and observed data. This method is illustrated by a case study of cardiac lead fracture. Different discount functions are used to cover a wide range of scenarios in which the type I error rates and power vary for the same number of enrolled patients. Incorporation of engineering models as prior knowledge in a Bayesian clinical trial design can provide benefits of decreased sample size and trial length while still controlling type I error rate and power.
Incorporation of stochastic engineering models as prior information in Bayesian medical device trials Tarek 
Introduction
Evaluation of medical devices via clinical trial is often a necessary step in the process of bringing a new product to market (FDA, 2014) . In some cases, the size and cost of such trials may delay patient access to new treatments or inhibit new product development (Luce, et al., 2009) . Incorporation of prior knowledge in premarket studies through use of Bayesian statistics has potential benefits of decreased sample size and trial duration. A common source of prior information is historical data from similar trials or real world performance of similar therapies. Issues arise when the variability among the historical and new groups is large, potentially due to differences in either the patient population, standard of care, or the device design (Ibrahim, et al., 2000; Hobbs, et al., 2011; Campbell, 2011; Pibouleau, et al., 2011; Wiens, et al., 2014; FDA, 2010; Kramer, et al., 2012) .
With recent advances in computational modeling it is now possible to simulate device outcomes based on engineering principles (Haddad, et al., 2014; Wilkoff, et al., 2013; Kovatchev, et al., 2009 ). However, there are few published examples of how these methods might positively affect the process of clinical evaluation (FDA, 2011; Mulugeta, et al., 2013) . In the case where the primary mechanisms contributing to device safety or effectiveness are well understood and modeled, it is possible to simulate the clinical outcomes for a new device in a virtual patient population. We will refer to these simulations as virtual patients.
Virtual patients describe a concept that represents a continuum of information that can be exchangeable for real patient outcomes in a clinical study. Information sources include computational model data as in our example but also may also include clinical data collected in different countries, predicate device data, and data sources not yet envisioned. It seems highly useful and natural to use these virtual patients to augment a study in a way that is analogous to how some Bayesian trials incorporate historical data as prior information.
The article introduces a novel method for augmenting a clinical trial with virtual patients using a discount function to discount the effective sample size based on the disagreement between the virtual and actual patient data. Our proposed framework may be especially useful for existing devices which have undergone engineering modifications and a clinical trial is required for regulatory purposes for the new version of the device.
Methods

Virtual patient model overview
This section provides an overview of our proposed framework for a virtual patient model. We introduce notation and discuss aspects of exchangeability, including the use of a discount function to discount the size of the virtual patients sample in the case of stochastic disagreement between the virtual and real patient outcomes. In section 3, we present a clinical trial design utilizing virtual patients for the next generation version of a hypothetical implantable cardioverter defibrillator (ICD) lead.
To implement this method, clinical outcomes for the virtual patients are simulated using a probabilistic engineering model, where a virtual patient cohort y 0 ¼ y 01 . . . y 0N 0 f grepresents N 0 individual virtual patient outcomes. Unlike historical data, the size of N 0 is limited only by computational resources and should be set large enough that uncertainty in the parameters of interest is reduced to a level below clinical significance and can be ignored. This is completely analogous to reducing sampling error and therefore the size N 0 should be commensurate with the clinical application, for example frequency of an event rate. Examples of virtual patient outcomes include blood glucose level control in diabetes therapy (Kovatchev, et al., 2009) or ICD lead fracture (Haddad, et al., 2014) .
Each y 0 can be thought of as a vector from a multivariate distribution, where η are parameters that index the distribution f 0 ðy 0 jηÞ. Note that f 0 ðy 0 jηÞ might not be based off of closed form known distributions but may instead be a complex set of stochastic statistical simulations or numerical physics-based engineering models. In some cases, there may be historical data on products with similar features that could be transformed in some way to simulate the performance of a new product.
The variation observed between the elements of y 0 represents variation one would observe in an outcome for a population that was given a treatment or medical device. Such outcome variability could be a result of patient factors such as variation in age, body composition, activity level, or disease state. This variation could represent device variation such as durability, pharmaceutical dose rate or physical dimensions. As an example, a model for failure of the load-bearing surfaces of a hip implant might include physical activity, body mass, and dimensional tolerances as inputs. Throughout this article, a zero subscript represents quantities associated with the virtual patient engineering model such as input data used to construct f 0 ðy 0 jηÞ.
The virtual patient distribution is determined by the parameters η with prior distribution q 0 ðηjD 0 Þ, where D 0 is data collected that can be used to construct these distributions. These data can be obtained by means such as bench testing, demographic information, or clinical data. As an example, a model for failure of the load-bearing surfaces of a knee replacement might be a function of the patient's number of daily steps which may follow a lognormal distribution. The mean and variance of this distribution may be estimated using data from pedometer studies.
Equation (1) is the multivariate predictive distribution of y 0 where η has been integrated out. The components within y 0 capture patient-to-patient variability for each realization of η. By drawing multiple y 0 cohorts we also capture the uncertainty in η, discussed in Section 2.4:
Because the maturity and credibility of virtual patient engineering models can vary widely, this method is most suitable in cases where there is a high level of previous experience with similar devices and the engineering model has been shown to be valid for use in the current application. The credibility assessment would ideally follow practices established by the relevant engineering and clinical communities (ASME, 2016). Due to the importance of the virtual patient model in assessing safety or efficacy of a new medical device in this context, a high level of interaction would be anticipated with the relevant clinical and regulatory entities. Although rigorous model validation activities can mitigate concerns about exchangeability, there may remain reasons for potential lack of agreement between engineering model and actual clinical outcome. These may be due to biological or physics-based simplifications, statistical assumptions, or unmeasured differences between the actual and modeled device and patient populations. It is therefore worthwhile to adjust the weight given to the virtual patients, i.e., the amount of borrowing from the virtual patient model. We will accomplish this by implementing a discount function that scales the effective number of virtual patients from zero to some predefined maximum according to the agreement with clinical data, discussed in Section 2.6.
Connection between the engineering model and the clinical model
In a clinical trial, the primary focus is on clinical outcomes such as the failure rate in patients, θ. That is, for real patient outcomes y, we assume a standard distribution f yjθ ð Þ indexed by the parameter of interest θ. If the engineering model accurately predicts clinical outcomes, then the outcomes of virtual and clinical patients will be similar. Therefore, the virtual patients should have relevant information about θ. Using this assumption, we interpret y 0 as having been generated from a distribution governed by the clinical parameter θ (i.e., y 0 e f ðy 0 jθÞ) instead of generated from q 0 ðy 0 jD 0 Þ (1) which as mentioned above may be complex with no closed form (see Figure 1 ). This interpretation is done for notational and mathematical convenience, as the power-prior approach discussed below requires the selection of a closed-form likelihood function governed by the clinical parameter θ. This assumption is similar to standard statistical practice where a standard distribution (e.g., normal) is selected because it fits the data reasonably well. Data from a well-developed engineering model will frequently be highly similar to clinical data (see, e.g., Haddad, et al., 2014) .
Note that f ðy 0 jθÞ and f yjθ ð Þ do not necessarily have to be the same probability density function. For example, f ðy 0 jθÞ could be lognormal and f yjθ ð Þ could be normally distributed, and in both cases θ could be the mean. In practice, if the distributions appear different (e.g., normal vs. lognormal), this may indicate a gap in the model or input data to the model which should be addressed by the sponsor. In such a case, one might rely less on the virtual patient model as a prior. In Section 2.5, we assume that the study sponsor has provided evidence that the distribution forms are similar enough to use the same likelihood for the clinical application of interest. In Section 2.6, we discuss the use of a discount function to adapt the number of virtual patients to account for disagreement between virtual and clinical data.
Incorporation of engineering simulation data using the power prior
Unlike historical data, simulated data have arbitrary and unlimited sample size and an appropriate weighting approach is required. Additionally, we would like a method for discounting the virtual patients in cases where there is heterogeneity between current and virtual patient study. We propose using the power-prior framework introduced by Ibrahim and Chen (Ibrahim, et al., 2000) to discount the prior generated by virtual patients. The power-prior method has several advantages for use in our methodology, summarized from De Santis (2007) and Ibrahim et al. (2015) :
(1) The power-prior method influences the heaviness of the tails of the prior, which directly influences the strength of the prior. This feature is important when there is heterogeneity between prior and current data. (2) The power prior is basically a likelihood function raised to a power, thereby sharing attractive properties of likelihood functions, particularly the ability to use conjugacy. (3) It is a well-understood method that is easy to implement and interpret. (4) Coupling the power-prior method with a flexible discount function allows an intuitive, computationally inexpensive approach for determining the strength of the prior.
Let y be a response vector of length nfrom the current study and LðθjyÞ ¼ Q n j¼1 f y j jθ À Á its likelihood function. Similarly, we can construct the likelihood function for a single cohort of virtual
θÞ. The cohort likelihood is then used to form a prior as shown next.
Let π 0 θ ð Þ denote the initial uninformative prior distribution for θ. We define the power-prior distribution of θ for the current study given one virtual patient cohort y 0 as:
where the parameter α 0 is a "discount" parameter that controls the influence of virtual patient data y 0 on π θjy 0 ; α 0 À Á . The discount parameter α 0 varies between 0 and 1. As α 0 approaches 1 more weight is given to the virtual patient data y 0 .
When historical data are used, α 0 represents the discount weight placed on its prior. We propose discounting the virtual patients by α 0 ¼ n 0 =N 0 , where n 0 is the effective sample size of the prior. See Section 2.6 for a discussion on how to determine n 0 . Equation (2) can then be rewritten as follows:
We can think of Equations (2) and (3) as down weighting the contribution of each virtual patient y 0j from f ðy 0j jθÞ to f y 0j jθ À Á n 0 =N 0 .
Incorporating multiple cohorts of virtual patients
Up until this point, we have dealt with only one virtual cohort y 0 . As noted above, we need to account for the uncertainty in the parameters governing the engineering model. To incorporate the entire distribution of q 0 y 0 jD 0 ð Þ, we integrate (3) over y 0 given D 0 to obtain the prior in (4):
The integral in (4) has no closed-form solution but one can generate data from π θjn 0 ; D 0 ð Þwith draws of y 0 from q 0 y 0 jD 0 ð Þ, then drawing θ from each instance of the power prior πðθjy 0 ; n 0 Þ (3). We repeat this process m 0 times using ordinary Monte Carlo methods, setting m 0 large enough to appropriately construct the posterior distribution for parameters η. This generates values of θ that incorporate the uncertainty in the virtual patient data y 0 while weighting virtual patient data to the effective prior sample size of n 0 . Note there are two sources of Monte Carlo error: the number of virtual patients in a cohort, N 0 and the number of cohorts, m 0 .
In order to obtain the posterior distribution for θ, we combine the power prior using (4) with the likelihood for data from the current study (y) as follows:
Implementation for conjugate priors
Many clinical outcomes have distributions with conjugate priors (e.g., blood pressure: normal/ normal, event rate: binomial/beta, survival: piecewise exponential/gamma, number of hospitalizations: Poisson/gamma and negative binomial/beta). In addition, the conjugacy properties are maintained after implementation of the power prior for these distributions (Ibrahim, et al., 2015) . Finally, if we assume y 0 and y follow the same distribution given θ (see Section 2.2) and thereby use the same likelihood form, then there are computational advantages. We can draw samples of θ from (5) using ordinary Monte Carlo procedures. For a single cohort, using a conjugate prior provides a closedform posterior:
In order to obtain a posterior distribution that is independent of y 0 , we integrate q θjy; y 0 ; n 0 ð Þover y 0 as opposed to integrating the prior π θjy 0 ; n 0 ð Þover y 0 , as was done in (4):
To draw samples from (7), which is equivalent to (5), we can draw posterior values of θ from each of the m 0 replicates of q θjy; y 0 ; n 0 ð Þobtained from each of the m 0 cohorts of y 0 . This gives us posterior values of θ that incorporate the uncertainty in current data y, as well as the uncertainty in the virtual patient data y 0 , while weighting virtual patient data so that the effective prior sample size will be n 0 . This process is shown in Algorithm 1. Without conjugacy, step 4 may require Markov Chain Monte Carlo sampling (De Santis, 2007) .
Algorithm 1: conjugate priors with fixed n 0 for i ¼ 1 . . . m 0 f 1. Draw η~q 0 ηjD 0 ð Þ 2. Draw y 0 , f 0 ðy 0 jηÞ # step 1 combined with step 2 is equivalent to drawing a sample from (1) 3. Construct q θjy; y 0 ; n 0 ð Þ# using (6) 4. Draw θ i , q θjy; y 0 ; n 0 ð Þ } Perform statistical inference on θ 1 ; . . . ; θ i ; . . . ; θ m 0
Below we show examples of Algorithm 1 for normal and binomial models. The binomial case is also illustrated in the section 3.
Normal distributed outcomes Assume y 0 and y come from normal distributions, where θ is the mean value of interest with an uninformative initial prior for θ, π 0 θ ð Þ. Furthermore, let σ
be the variance and mean for y 0 . Then, using (2) and (3), the virtual prior becomes π θjy 0 ; n 0 ð Þ¼N y 0 ;
By using Equation (6) and because of the conjugate nature of the normal distribution, the posterior is also normal:
Equation (8) is still conditional on just one set of y 0 as well as σ 2 . To obtain samples from q θjy; n 0 ; D 0 ð Þ , construct q θjy; σ 2 ; y 0 ; n 0 ð Þusing (8) for each virtual patient cohort y 0 , as well as simulated values from q σ 2 jy ð Þ which is an inverse gamma distribution. We then draw a posterior value of θ for each of the m 0 cohorts.
Binomial distributed outcomes
Assume y 0 and y come from binomial distributions where θ is the event rate of interest and the initial prior for θ, π 0 θ ð Þ ¼ beta a 0 ; b 0 ð Þ follows a beta distribution. Then the posterior is as follows:
Similarly, we obtain posterior values of θ by constructing q θjy; y 0 ; n 0 ð Þusing (9) for each virtual patient cohort y 0 .
Using discount functions to determine n 0
We want the number of virtual patients n 0 to be large to give enough information to the study but small enough to allow the real data to govern the trial outcome. A simple approach would be to determine n 0 so that the type I error rate and bias would be controlled at a pre-specified level. However, instead of determining n 0 before we have some idea of how well the virtual patients resemble the real patients, we may want to adjust n 0 once we observe some real patients in the clinical trial. In this section, we use a discount function to adjust n 0 such that when the virtual patients are very different from the actual patients, n 0 will shrink to 0. Alternatively, if there is substantial agreement, n 0 can be as large as a predefined maximum number of virtual patients n max . Based on the experience of the authors, n max should be selected based on factors including credibility of the virtual patient model, clinical study logistics, allowable type I error rate, and overall stakeholder comfort with replacing real patients with virtual patients. The discount function can be chosen so that the trial achieves desired power while controlling the type I error rate and bias at the pre-specified significance level. The discount function procedure is performed as an initial step, thus allowing α 0 to be treated as a fixed value in the posterior estimation process.
Suppose we obtain the posterior distribution of θ given the current data with a minimally informative prior π 0 θ ð Þ, call this quantity θ flat , where θ flat , qðθjy; n 0 ¼ 0Þ. Let us now construct a posterior distribution for θ given the virtual patient data alone for one cohort y 0 , call this θ 0 , qðθjy 0 Þ. Note that draws of θ 0 conditioned on a cohort should have negligible variation due to a large value for N 0 . We can then stochastically compare the distribution of θ 0 to θ flat as P θ flat θ 0 ð Þ . This quantity can be computed by comparing one drawn sample of θ 0 conditioned on the ithcohort and one drawn sample of θ flat . Repeat this process for each of the m 0 cohorts:
Iðθ flat;i θ 0;i Þ
Expression (10) is an indirect way of comparing y to y 0 and will have a value from 0 to 1, indicating the probability that the virtual patient outcome is stochastically larger than the real patient outcome. The number of cohorts m 0 should be set large enough to minimize Monte Carlo error to an acceptable level. This convention assumes that a larger θ is a negative outcome such as an adverse event rate and that we wish to be conservative when borrowing. As p gets small, we wish to include fewer virtual patients in the augmented trial (see Figure 2) . We now construct a discount function that relates p from (10) to n 0 . We define a maximum number of virtual patients n max and discount function F p ð Þ such that n 0 ¼ n max F p ð Þ. F is defined such that if p is large enough, n 0 ¼ n max and if p is small, n 0 approaches zero. The Weibull cumulative distribution function is highly flexible for most situations:
We restrict λ < 1 to allow n 0 ¼ n max as p approaches 1. The k parameter controls the rate of decrease in virtual patients allowed as p declines. This approach has the ability to be applied to any statistical model, whereas other approaches (Hobbs, et al., 2011 ) may require unique procedures for different statistical models. In addition, this method is straightforward to implement and can be used in conjunction with conjugate priors, allowing for simple and computationally efficient implementation. Note that when θ 0 is conservative (i.e., larger) relative to the current data, p approaches 1 and we would still get full weight for the prior n 0 ¼ n max ð Þ . This does not necessarily penalize the final outcome, compared to a study with just the current data all alone, because we can gain precision from a larger sample size. In nearly all foreseeable applications the prior comfortably resides in the domain of the alternative hypothesis; otherwise the study sponsor should not run the trial. Figure 4 demonstrates how a conservative prior can still produce tighter confidence intervals than study data alone. Nonetheless, in some cases, a two-sided function may be a desirable alternative to the onesided Weibull discount function. An example two-sided function is Equation (12). Note that the top portion of (12) is identical to (11): Figure 2 . Comparison between data from virtual patients and current study used to determine effective virtual patient sample size. A parameterized discount function relates n 0 to p.
We can consider the parameters of this Weibull discount function as meta-parameters to be optimized outside of the estimation of θ. We can simulate the trial many times with different values of k and λ to determine the discount function with optimal type I and II error rates; for example, a grid search with k from 0 to 10 and λ from 0 to 1 could be used. Once the discount function is determined, n 0 is determined. A suitable approach is given below in Algorithm 2. Figure 3 shows candidate discount functions from (11) and (12) 4. Simulate the trial many times for each of the true θ values from step 3 5. From step 4, construct type I error rate and power curve 6. Repeat steps 2-5 for different values of k and λ to optimize type I error and power curve 7. Once k and λ are chosen, n 0 is determined As an example of the effect of the discount function, Figure 4 shows credible intervals in scenarios where the virtual patient prior is optimistic, similar to, and pessimistic relative to the current study. In this example the outcome is binomial, where n ¼ n max ¼ 100 and the virtual patient model is θ 0 e beta 5; 500 ð Þ, equivalent to a historical data set with four events out of 503 patients or 1% failure rate for the virtual patients. Note that although the prior in this example has the ability to incorporate the equivalent of 503 virtual patients, the power-prior methodology coupled with the notion of n max allows us to set a maximum strength of 100 patients. The credible intervals for the current data are obtained using a non-informative prior, beta 1; 1 ð Þ. The discount function parameters are λ ¼ :2; k ¼ 2, corresponding to the dashed blue curve in Figure 3 .
The panels in Figure 4 can be interpreted as follows:
• Top panel: the prior is optimistic relative to the current study and the discount function produces a substantial penalty, resulting in almost no weight to the prior. The posterior is essentially the same as in the current study.
• Middle panel: the current data are very similar to the prior. The discount function penalty is small, resulting in nearly full weight to the prior. Because the agreement is good, the posterior is similar to both the prior and current study.
• Bottom panel: the current data have better performance than the prior. The discount function produces close to full weight and the posterior is a balance between the prior and current study. Note that even though the current data has better performance than the prior, the confidence intervals are tighter for the posterior than for the current study.
When there are multiple parameters, the discount function in (11) can be applied to each parameter separately, yielding P ¼ ðp 1 ; p 2 ; . . . p W Þ. Alternatively, a composite function of the multiple parameters values can be calculated.
Model updating and adaptive design
We have shown that the amount of information borrowed from the multiple cohorts of virtual patients (measured by the prior effective sample size, n 0 ) depends on the similarity between the virtual patient responses and the real patient responses. However, prior to collecting data on real patients, it may be difficult to specify n 0 because we do not know how similar the virtual patients are to the real patients. Therefore, our method works best within an adaptive design framework whereby we update n 0 at one or more interim looks based on the similarity of the virtual and real patients to adapt the number of real patients needed to meet the study endpoints. In fact, initial data on real patient characteristics and use conditions could be used to better describe the posterior distributions q 0 ηjD 0 ð Þ, yielding more accurate virtual patients from the simulation. Later interim looks could be used to modify n 0 . Naturally, such modifications should be pre-specified to occur at an interim look in order to protect the integrity of the virtual patient model and clinical trial.
Suppose the example in Section 2.1 collected in-vivo loading data an initial interim look. The new data would update the engineering prior, resulting in a new failure rate prediction. If the new data indicated higher failure rates than the original assumption for the input data the discount function would penalize the virtual patients. In order to maintain the desired power for the clinical trial or quickly cut losses with a futility decision, we might need to adjust the number of real patients from what was originally planned based on the initial engineering prior information. After the initial adjustment to the engineering model additional interim looks could be used to determine the amount of borrowing from virtual patients and thus the sample size for the clinical trial. As with any planned adaption, sensitivity analyses of study characteristics to the results of an interim look should be performed in the design stage of the study.
Results
Scenario for a virtual patient engineering model
As an example of a probabilistic engineering model, we consider the case of cardiac lead fracture rate inside the heart, similar to Haddad et al. (2014) . The heart contracts with every heartbeat, causing the lead to bend. Lead fracture occurs when the accumulated cycles of bending stress exceed the fatigue strength of the lead. In this example, the model assumes that the number of cycles to fracture, C, depends on the applied bending stress, S, measured as geometric curvature. We first collect samples of bending stress D 0S ¼ s 1 . . . s n f gby imaging leads in real patients throughout a full cardiac cycle (Baxter, et al., 2001 ). Meanwhile, a benchtop fatigue strength test can be used to obtain samples of the number of cycles to fracture D 0C ¼ c 1 . . . c n f g , given a particular applied bending stress S. In our example, D 0 represents data collected from engineering measurements.
The statistical model assumes that S follows a distribution f 0 Sjη S À Á parametrized by η S . This distribution reflects variability from patient anatomy and physician implantation technique. Given S, we assume that C follows the distribution f 0 ðCjS; η C Þ with parameters η C . The variability of C given a particular S can be due to manufacturing tolerances or material properties. The uncertainty about η ¼ η S ; η C À Á is described by prior distributions q 0 η S À Á and q 0 η C À Á . The data collected in D 0S and D 0C are used to derive posteriors for η: q 0 η S jD 0S À Á and q 0 ðη C jD 0C Þ which are used by the engineering model to generate virtual patients.
Engineering model outputs are often not immediately translated into clinical outcomes. However, in certain circumstances, one can obtain relevant clinical outcome information from engineering data. For example, the authors in Haddad et al. (2014) relate fatigue strength and use condition variables to failure rate of cardiac leads in a patient population. In the example introduced above, we assume that we have identified a suitable transfer function t, relating bending stress S and number of cycles C to a clinically relevant time-to-lead fracture; y 0 ¼ t C; S ð Þ for survival analysis. In this case, the engineering model is the function t. Using the joint distribution of S and C above, we can represent the distribution of
f grepresent a cohort of N 0 individual virtual patient times to lead failure with joint distribution f 0 y 0 jη ð Þ given η. To simulate these virtual patient outcomes, first we draw the parameters η S ; η c À Á from their respective engineering posterior distributions as described above. We then draw values of S given η S and values of C given S and η C . Performing the transformation t C; S ð Þgenerates the cohort y 0 . Algorithm 3 shows the steps for the simulation:
Algorithm 3: Preclinical engineering model In our example, the clinical outcome of interest is years to lead failure. Combining the two loops together is equivalent to the numerical integration of (1). The nested loops in Algorithm 3 will allow us to better compare the virtual patients to the patients in the clinical study, due to the variability captured in the virtual patient population.
For this example, the transfer function is to divide C by the number of heartbeats per year to obtain time to failure in years. In Figure 5 , we use Algorithm 3 to generate a Kaplan-Meier curve for each of the m 0 vectors of η.
Case study of cardiac lead failure (binomial)
Here, we utilize the engineering model described above to generate lead failures in virtual patients and to design a study for a hypothetical cardiac lead. The failure rate in the actual patients at a particular time point can be expressed as a proportion θ.
Suppose we want to test the null hypothesis H 0 : θ ! 5%. We assume the posterior from the virtual patient model gives us y 0 , binomialðn 0 ; θ 0 Þ and θ 0 , beta 5; 500 ð Þ, equivalent to an expected failure rate of 1% in the virtual patients. We implement the procedure described above and compare the augmented trial to a traditional trial scenario where the size of the trial is n ¼ 100 with a noninformative prior (giving 75% power to reject the null under a 1% failure rate). We assume a highly credible model and agreement between sponsor and regulatory stakeholders that n ¼ n max ¼ 100. In practice the selection of n max needs to be considered in context of desired type I error rate and power. For the same discount function, as n max increases, power and type I error rate will increase. Figures 6 and 7 illustrate how the discount function controls type I error rate and power to the desired level by controlling n 0 . Figure 5 . Kaplan-Meier survival curves generated from an engineering model, similar to (Haddad, et al., 2014) . Curves represent samples from q 0 ðy 0 jD 0 Þ.
In Figure 6 , we show the impact on operating characteristics when the Weibull discount function described above has parameters between 0:01 < λ < 0:17 and 2 < k < 4. For power we assume a true failure rate of 1%. From the response surface, note that it is possible to achieve a wide range of type I error rates and power. Figure 7 illustrates power curves generated from different assumptions (i.e., n 0 ¼ 0, various discount functions, and n 0 ¼ n max ). We also show the density of the underlying virtual patients. Note that the trials with zero and full borrowing represent extremes of the discount function. As an example, compare the trial with discount function parameters of λ ¼ 0:03; k ¼ 4 to the trial with full borrowing. Power is highest in the trial with full borrowing. However the discount function trial is desirable due the substantial reduction in type I error (14% vs. 26%) with moderate reduction in power at the expected 1% failure rate (93% vs. 97%). Recall that all simulations in Figures 6 and 7 have the same number of enrolled patients.
The pseudo code in Algorithm 4 generates posterior values of θ for a particular n max and discount function parameters k and λ. y ¼ y 1 ; y 2 ; . . . ; y n f g # real data where each y k is either a 0 or 1 
Discussion and conclusion
We have presented a framework for an engineering model that generates virtual patients and a method to combine these virtual patients with clinical study data. A discount function controls the number of virtual patients up to a maximum number (n max ) based on similarity between the real patients and virtual patients. The discount function approach can also be applied to traditional Bayesian applications with informative priors from real historical data.
The maximum number of virtual patients will depend on the model credibility as well as the severity of the consequences of bias or a type I error. The study sponsor must also ensure that the engineering model appropriately accounts for uncertainty.
In contrast to approaches that describe the power parameter α 0 as a random value to be estimated (Ibrahim, et al., 2015) , this article describes a two-stage approach. In the first stage we pre-specify a maximum strength of the virtual patients (n max ) and a discount function that penalizes α 0 based on disagreement with the current data. These pre-specifications are tailored specifically to the clinical application and virtual patient model credibility. In the second stage, α 0 is used as a fixed value to all posterior parameter estimation procedures, reducing computational cost and enabling closed-form solutions (Ibrahim, et al., 2015) .
We acknowledge the challenges with the use of hierarchical models when there is only one source of prior evidence (Hobbs, et al., 2011) and that the power-prior methodology with a fixed power parameter applies more readily to one source of prior information. The discount function approach allows for flexibility in the attenuation of the influence of virtual patients within the power-prior method as mentioned by Neelon and O'Malley (2010) . For example, when n is large, a relatively lax discount function can be used to maintain virtual patient weight in cases of statistical, but not clinically relevant differences. Alternatively, when n is small the discount function would likely be more stringent.
Additional distinguishing features of our methodology include:
(1) This approach provides a natural method for validation of engineering models by clinical evaluation. (2) There is not a practical limit on the number of virtual patients, only limits to the weight given the virtual patient data. The ability to simulate large numbers of virtual patients, including the potential for minority populations such as pediatrics, allows for robust expression of variability. (3) The discount function methodology that has been developed here can be used to limit the weight given to virtual patients, controlling type I error rate in the case of an optimistic engineering model. The discount function is straightforward and can be easily applied to any statistical model. (4) The power parameter explicitly describes the weight of the prior in terms of number of virtual patients, making it more clear to non-statisticians how much weight is given to the prior. (5) Engineering parameters can be updated at interim looks as additional clinical data is acquired, allowing for adaptive refinement of the engineering model.
We believe that the proposed methodology can improve clinical trial efficiency by utilizing engineering models for medical devices which can result in potentially faster access to new therapies for patients.
